Athersys, Inc. (ATHX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 0.2772 |
| Open | 0.2812 |
| Bid | 0.2814 x 1000 |
| Ask | 0.2871 x 1100 |
| Day's Range | 0.2800 - 0.2900 |
| 52 Week Range | 0.1700 - 1.8100 |
| Volume | |
| Avg. Volume | 12,955,956 |
| Market Cap | 74.852M |
| Beta (5Y Monthly) | -1.26 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3570 |
| Earnings Date | Aug 11, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.63 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for ATHX
Related Research
- Athersys, Inc.Analyst Report: Johnson & JohnsonJohnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. Geographically, just over half of total sales are generated in the United States.RatingFair ValueEconomic Moat4 months agoMorningstar
- Benzinga
Radiation Countermeasure Study Data For U.S. Defense Department Gets First Readout
Athersys Inc (NASDAQ: ATHX) has announced the results of a radiation countermeasure study that showed intravenous MultiStem (invimestrocel) administration provided benefit in an animal model of acute radiation syndrome (ARS). The results demonstrate that the administration of MultiStem cells increased survival in treated animals compared to vehicle treatment, resulting in higher body weights in surviving animals and positive trends in the recovery of the hematopoietic system. Also Read: Athersys
- Business Wire
Athersys Announces Favorable Preclinical Results for MultiStem® Treatment in Defense Department Radiation Countermeasure Study and Upcoming Webinar to Review Preclinical Research With MultiStem Across Multiple Indications
CLEVELAND, August 08, 2022--Athersys, Inc. (Nasdaq: ATHX) announces today results of a radiation countermeasure study conducted by the Armed Forces Radiobiology Research Institute (AFRRI), a Department of Defense research laboratory under the leadership of the Uniformed Services University of the Health Sciences, that showed intravenous MultiStem® (invimestrocel) administration provided benefit in an animal model of acute radiation syndrome (ARS). The results demonstrate that the administration
- American City Business Journals
Athersys hires turnaround consultant as interim CFO
Athersys Inc., the Cleveland-based regenerative medicine company, has hired turnaround specialist Ankura Consulting Group LLC and appointed the firm's senior managing director, Kasey Rosado, as its interim chief financial officer. Athersys lost its previous CFO, Ivor Macleod, in June through a restructuring — which included cutting its workforce by as much as 70% — aimed at reducing costs and making it an attractive investment for potential financial or strategic partners. New York-based Ankura offers management consulting and expert services "at critical inflection points," including corporate restructuring, bankruptcy, dispute and litigation, according to its LinkedIn page.
